Suppr超能文献

在含有治疗浓度的组织型纤溶酶原激活剂或其他溶栓剂的血浆样本中,低温下的纤溶酶原激活。

Plasminogen activation at low temperatures in plasma samples containing therapeutic concentrations of tissue-type plasminogen activator or other thrombolytic agents.

作者信息

Rijken D C, Seifried E, Barrett-Bergshoeff M M, Dooijewaard G

机构信息

Gaubius Institute TNO, Leiden, The Netherlands.

出版信息

Thromb Haemost. 1990 Aug 13;64(1):47-52.

PMID:2125758
Abstract

It is known that in vitro plasminogen activation in blood samples taken during thrombolytic therapy with tissue-type plasminogen activator (t-PA) may lead to artefactually low fibrinogen and alpha 2-antiplasmin values. To mimic this phenomenon, pooled normal plasma was supplemented with 2.5 micrograms/ml t-PA and incubated at various temperatures. The rates of fibrinogen degradation and alpha 2-antiplasmin consumption were most pronounced at 37 degrees C, were less pronounced at 25 degrees C, but surprisingly, did not further decrease at 10 degrees C, 0 degrees C or -8 degrees C. In contrast, when plasma was supplemented with 160 IU/ml urokinase or 30 IU/ml streptokinase, the rates of fibrinogen degradation and alpha 2-antiplasmin consumption gradually decreased with incubation temperature and were negligible at 10 degrees C and lower temperatures. The rate of plasminogen activation also decreased gradually with temperature in mixtures of purified fibrinogen, plasminogen, alpha 2-antiplasmin and t-PA. These results imply that, in a plasma milieu, additional factors with a stimulatory activity are involved in t-PA-induced plasminogen activation at around 0 degrees C. The abnormally high reaction rate at low temperatures explains in vitro plasminogen activation observed during the processing of t-PA-containing blood samples. In contrast to the activation of plasminogen by t-PA, the slow inhibition of t-PA (2.5 micrograms/ml) by proteinase inhibitors in plasma could be minimized to a negligible level by keeping the plasma samples at 0 degrees C. This makes it possible to reliably monitor t-PA activity during thrombolytic therapy.

摘要

众所周知,在用组织型纤溶酶原激活剂(t-PA)进行溶栓治疗期间采集的血样中,体外纤溶酶原激活可能导致纤维蛋白原和α2-抗纤溶酶值出现人为降低。为模拟这一现象,向混合的正常血浆中添加2.5微克/毫升的t-PA,并在不同温度下孵育。纤维蛋白原降解率和α2-抗纤溶酶消耗率在37℃时最为明显,在25℃时不太明显,但令人惊讶的是,在10℃、0℃或 -8℃时并未进一步降低。相比之下,当血浆中添加160国际单位/毫升的尿激酶或30国际单位/毫升的链激酶时,纤维蛋白原降解率和α2-抗纤溶酶消耗率随孵育温度逐渐降低,在10℃及更低温度时可忽略不计。在纯化的纤维蛋白原、纤溶酶原、α2-抗纤溶酶和t-PA的混合物中,纤溶酶原激活率也随温度逐渐降低。这些结果表明,在血浆环境中,在0℃左右时,t-PA诱导的纤溶酶原激活涉及具有刺激活性的其他因素。低温下异常高的反应速率解释了在处理含t-PA血样过程中观察到的体外纤溶酶原激活现象。与t-PA激活纤溶酶原不同,通过将血浆样本保持在0℃,血浆中蛋白酶抑制剂对t-PA(2.5微克/毫升)的缓慢抑制作用可降至可忽略不计的水平。这使得在溶栓治疗期间可靠地监测t-PA活性成为可能。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验